Aclaris Therapeutics, Inc.
ACRS· Nasdaq
ACRSAclaris Therapeutics, Inc.
Filed Feb 25, 2021 · 10-K · 56 days after period end · 0001558370-21-001717
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $1.58M | $1.10M | $3.67M | $999.00K |
| Net Income | -$13.17M | -$18.59M | -$38.55M | -$22.93M |
| EPS Diluted | — | — | -$0.99 | -$0.74 |
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2020 · filed Feb 25, 2021 · 56 d after period end
